Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease

Maike Hartlage-Rübsamen · Alexander Waniek · Juliane Meißner · Markus Morawski · Stephan Schilling · Carsten Jäger · Martin Kleinschmidt · Holger Cynis · Astrid Kehlen · Thomas Arendt · Hans-Ulrich Demuth · Steffen Roßner

Abstract The brains of Alzheimer’s disease (AD) patients are characterized by deposits of Abeta peptides and by accompanying chronic inflammation. Here, we provide evidence that the enzyme isoglutaminyl cyclase (isoQC) is a novel factor contributing to both aspects of AD pathology. Two putative substrates of isoQC, N-truncated Abeta peptides and the monocyte chemoattractant chemokine CCL2, undergo isoQC-catalyzed pyroglutamate (pGlu) modification. This triggers Abeta aggregation and facilitates the biological activity of CCL2, which collectively results in the formation of high molecular weight Abeta aggregates, glial cell activation, neuroinflammation and neuronal cell death. In mouse brain, we found isoQC to be neuron-specifically expressed in neocortical, hippocampal and subcortical structures, localized to the endoplasmic reticulum and Golgi apparatus as well as co-expressed with its substrate CCL2. In aged APP transgenic Tg2576 mice, both isoQC and CCL2 mRNA levels are up-regulated and isoQC and CCL2 proteins were found to be co-induced in Abeta plaque-associated reactive astrocytes. Also, in mouse primary astrocyte culture, a simultaneous up-regulation of isoQC and CCL2 expression was revealed upon Abeta and pGlu-Abeta stimulation. In brains of AD patients, the expression of isoQC and CCL2 mRNA and protein is up-regulated compared to controls and correlates with pGlu-Abeta load and with the decline in mini-mental state examination. Our observations provide evidence for a dual involvement of isoQC in AD pathogenesis by catalysis of pGlu-Abeta and pGlu-CCL2 formation which mutually stimulate inflammatory events and affect cognition. We conclude that isoQC inhibition may target both major pathological events in the development of AD.

Introduction

Amyloid pathology and neuroinflammation including activation of glial cells are key hallmarks of the neuropathology in brains of Alzheimer’s disease (AD) patients. Both Abeta peptides and pro-inflammatory cytokines/chemokines are reported to interfere with neuronal survival and with proper synaptic function, resulting in cognitive decline [6, 20, 21, 62]. The relation between the actual clinical status of the patient and the degree of neuropathology can be assessed by testing cognitive function and by imaging techniques monitoring hippocampal shrinkage, Abeta deposition and microglial activation [26, 29, 55]. Abeta peptides are generated by proteolytic processing of the amyloid precursor protein (APP) and may undergo post-translational modification such...
as N-terminal truncation and subsequent cyclization of N-terminal glutamate (Glu) into pyroglutamate (pGlu) [43, 46, 47, 56]. The resulting pGlu-Abeta peptides (1) are major constituents of Abeta deposits in sporadic and familial AD [33, 40, 41, 46], (2) possess a high aggregation velocity [13, 18, 31, 44, 51, 54], (3) display resistance to degradation by peptidases [45] and (4) are particularly neurotoxic to primary neurons, neuronal cell lines
Fig. 1 Expression of isoQC in mouse brain. a The enzyme isoQC is expressed almost ubiquitously in numerous neocortical, hippocampal, subcortical and cerebellar brain structures of wild-type mouse brain at 4 months of age as evidenced by immunohistochemical labeling in sagittal sections. b This labeling is highly specific as shown by the absence of staining in brain tissue of isoQC knock-out mice. On the other hand, in QC knock-out brain tissue the isoQC labeling is not affected. c In coronal sections, some brain regions with particularly high expression levels of isoQC can be distinguished. These include piriform cortex, 2 indusium griseum, 3 entorhinal cortex, 4 habenular nucleus, 5 hippocampus, 6 parietal cortex, 7 Edinger–Westphal ncl., 8 locus coeruleus, 9 cochlear nucleus and Purkinje cells of the cerebellum.

Table 1 Coktails of antibodies used for double and triple labeling immunohistochemistry

| Primary antibody | Dilution | Host | Company | Secondary antibody |
|------------------|----------|------|---------|--------------------|
| isoQC 3285       | 1:100    | Rabbit | Invitrogen | Bio-donkey anti-rabbit + SA-Cy2 |
| HuC/D            | 1:100    | Mouse  | Probiodrug  | Cy3 donkey anti-mouse           |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| GFAP             | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| WGA Alexa555     | 1:500    | Lectin | Invitrogen |                   |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| CCL2 sc-1784     | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| calreticulin     | 1:200    | Chicken | Abcam   | Cy3 donkey anti-chicken       |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| syntaxin-6       | 1:100    | Mouse  | Abcam     | Cy3 donkey anti-mouse         |
| CCL2 sc-1784     | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| HuC/D            | 1:100    | Mouse  | Invitrogen | Cy3 donkey anti-mouse         |
| CCL2 sc-1784     | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| GFAP-Cy3         | 1:1,000  | Mouse  | Sigma     |                    |
| CCL2 MAB2791     | 1:1,000  | Mouse  | R&D Systems | Bio-donkey anti-mouse + SA-Cy2 |
| GFAP             | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| CCL2 sc-1784     | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| Iba-1            | 1:100    | Rabbit | Wako      | Cy3 donkey anti-rabbit        |
| TolPro           | 1:10,000 | Mouse  | Invitrogen |                   |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| CCL2 sc-1784     | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| GFAP             | 1:1,000  | Mouse  | Sigma     | Cy3 donkey anti-mouse         |
| isoQC 3285       | 1:100    | Rabbit | Probiodrug  | Bio-donkey anti-rabbit + SA-Cy2 |
| CCL2 sc-1784     | 1:100    | Goat   | Santa Cruz | Cy3 donkey anti-goat           |
| pGlu-Abeta       | 1:100    | Mouse  | Synaptic Systems | Cy3 donkey anti-mouse |

Secondary antibodies were all from Dianova and used at a dilution of 1:400 (biotinylated) and 1:200 (fluorochromated).

and neurons of APP transgenic animals in vivo [1, 2, 38, 44, 61]. Interestingly, pGlu-modified Abeta peptides in brains of AD patients and transgenic mouse models were reported to be closely associated with [11C]Pittsburgh Compound-B (PIB) autoradiographic signals [28].

The pGlu-Abeta peptide modification has been demonstrated to be catalyzed by glutaminyl cyclase (QC) in vitro [50] and in vivo [11, 12, 49, 53]. Recently, we observed robust QC expression in mouse and human brain in AD-vulnerable subcortical regions such as nucleus basalis Meynert, locus coeruleus and Edinger–Westphal nucleus [35] and in a subpopulation of neocortical neurons and of GABAergic interneurons in hippocampus [15, 16]. Chronic pharmacological inhibition or genetic ablation of QC activity in animal models of AD resulted in reduced pGlu-Abeta peptide generation and in ameliorated behavioral deficits [2, 22, 53], while QC overexpression aggravated neuropathology and cognitive dysfunction in transgenic mice [22].

Recently, a Golgi-resident isoenzyme of QC with identical enzymatic characteristics was discovered [10, 59]. In cell-free assays, both enzymes convert a variety of substrates with similar kinetics and are inhibited by a number of inhibitors from different chemical classes at comparable Ki values [59]. However, based on the cell type-specific expression and subcellular localization, QC and isoQC appear to have distinct physiological substrate profiles. For example, isoQC—but not QC—catalyzes the pGlu modification of the monocyte chemoattractant protein-1 (MCP-1; also designated CCL2) and thereby stimulates monocytic infiltration into the peritoneum of mice in the thioglycollate-induced peritonitis model [8]. CCL2 lacking the pGlu modification has reduced chemoattractant activity and is less resistant to proteolytical degradation.
by aminopeptidases [8]. Recent studies demonstrated that isoQC-catalyzed pGlu-CCL2 also contributes to inflammatory tissue damage in mouse models of septic arthritis and non-alcoholic fatty liver disease [9, 19]. Since the tissue damage is less severe in isoQC knock-out mice and has been shown to be ameliorated by isoQC inhibitors, it points towards a role of isoQC in chronic inflammatory processes.

In AD, CCL2 was also shown to play a dominant role in chronic inflammation [58] and to be associated with a faster rate of cognitive decline at early stages of the disease [60]. Likewise, CCL2 overexpression accelerated Abeta oligomer and diffuse plaque formation and caused deficits in spatial and working memory in mouse models of AD [25, 63], while expression of a dominant negative CCL2 variant ameliorated Abeta pathology and reduced memory impairments [24]. Chronic neuroinflammation triggered by a variety of stimuli including—but not limited to—Abeta peptide aggregates was shown to contribute to cognitive decline in AD patients [32, 42].

So far, the enzymatic mechanisms of pGlu-CCL2 formation in brain, the brain region and cell type-specific expression pattern of isoQC, its subcellular localization and correlation with Abeta pathology in brains of transgenic mice and AD patients are not yet known and were therefore the subject of this study. Collectively, we here report for the first time a role for isoQC in CCL2 maturation and bioactivity in brain which may contribute to aspects of AD pathology and to the manifestation of clinical symptoms.

### Materials and methods

#### Mouse brain tissue

Brain tissue of wild-type and APP transgenic Tg2576 mice at the postnatal age of 4 and 17 months was used for immunohistochemistry, ELISA and quantitative reverse transcriptase PCR (qRT-PCR) analyses. IsoQC knock-out mice described in Cynis et al. [8] served as negative control for the specificity of the isoQC antibodies employed. For immunohistochemistry, mice were anesthetized with pentobarbital and transcardially perfused with 25 ml of phosphate-buffered saline (PBS, 0.01 M; pH 7.4) followed by perfusion with 25 ml of 4 % paraformaldehyde in phosphate buffer (PB, 0.1 M; pH 7.4). Brains were removed from the skull and post-fixed by immersion in the same fixative overnight at 4 °C. After cryoprotection in 30 % sucrose in 0.1 M PB for 3 days, brains were snap-frozen in n-hexane and stored at −20 °C. Coronal sections (30 µm) were cut on a sliding microtome and collected in 0.1 M PB.

For biochemical analyses, mice were sacrificed by decapitation at the postnatal age indicated, brains were removed from the skull, and neocortex was prepared, snap-frozen in liquid nitrogen and stored at −80 °C pending qRT-PCR or ELISA analyses.

#### isoQC and CCL2 antibodies

Since the specificity of the immunohistochemical isoQC labeling is critical for this study, we tested a number of
Fig. 2 Neuronal isoQC expression, subcellular localization and co-expression of CCL2 in mouse brain and primary neurons. a IsoQC was strictly co-localized with the neuronal marker HuC/D in brain sections of 17-month-old wild-type mice demonstrating a neuron-specific expression. Cells which did not display HuC/D immunoreactivity were also negative for isoQC labeling (arrows). b IsoQC was co-localized with cellular compartment markers calreticulin and syntaxin-6, consistent with a subcellular localization in endoplasmic reticulum and Golgi apparatus. c The putative isoQC substrate CCL2 was found to be co-expressed by isoQC-immunoreactive neurons in cortex of wild-type mice (top) and in primary neuronal cultures (bottom). d The conversion of CCL2 by recombinant isoQC was analyzed in a kinetic assay. The progress curve (black trace) was in accordance with a curve modeled according to the integrated form of the Michaelis–Menten equation (red trace), enabling the determination of the kinetic parameters $K_M$ (19.8 ± 0.4 μM) and $k_{cat}$ (0.76 ± 0.01 s$^{-1}$).
isoQC antibodies in brain tissue of wild-type, QC knock-out and isoQC knock-out mice. The antiserum 3285 (Probiodrug, Halle/Saale, Germany) allowed for the specific immunohistochemical detection of isoQC in mouse brain. This staining was completely absent in brains of isoQC knock-out mice, but not in brains of QC knock-out mice (Fig. 1).

Additionally, different anti-CCL2 antibodies derived from mouse and goat, respectively, were tested. The goat anti-CCL2 antiserum sc-1784 (St. Cruz) and the mouse anti-CCL2 antibody (clone 4B8; Probiodrug, Halle/Saale, Germany) showed a distinct staining pattern for CCL2 around nuclei of mouse primary neurons as well as of neurons in mouse brain tissue. The other tested antibodies displayed more diffuse and undifferentiated staining of brain sections or unspecific labeling of blood capillaries. In human brain tissue, the goat antiserum sc-1784 and the
mouse monoclonal antibody MAB2791 (R&D Systems) demonstrated distinct neuronal CCL2 labeling comparable to the staining pattern observed in mouse brain.

Based on specificity and the superior signal-to-background ratio, the rabbit anti-isoQC antiserum 3285 and the goat anti-CCL2 antiserum sc-1784 were selected for immunohistochemistry in mouse brain tissue and the rabbit anti-isoQC antiserum 3285 as well as the monoclonal anti-CCL2 antibody MAB2791 was used in human brain tissue.

Immunohistochemistry to detect isoQC was performed using the affinity-purified rabbit antiserum 3285 at a dilution of 1:500. After inactivation of endogenous peroxidase with 0.6 % H$_2$O$_2$ in 0.1 M TBS for 15 min and blocking of unspecific binding sites with 5 % normal goat serum in TBS containing 0.3 % Triton-X100, brain sections were incubated in the same solution with the primary antibody
at 4 °C overnight in a humid chamber on a shaker. The following day, sections were incubated with secondary biotinylated goat anti-rabbit antibodies (Dianova; 1:400) in TBS-2 % bovine serum albumin (BSA) for 60 min at room temperature followed by the ABC method which comprised incubation with complexed streptavidin-biotinylated horse-radish peroxidase (Invitrogen). Incubations were separated by washing steps (3 times 5 min in TBS). The isoQC immunoreaction was visualized by incubation with 4 mg 3,3′-diaminobenzidine (DAB) and 2.5 µl H2O2 per 5 ml Tris buffer (0.05 M, pH 7.6) for 1–2 min.

Double immunofluorescent labeling procedures

To reveal (1) the cell type-specific expression, (2) the intracellular localization and (3) the co-localization of isoQC with its putative substrate CCL2, the rabbit anti-isoQC antiserum 3285 was used in combination with mouse monoclonal antibodies or a polyclonal antiserum from goat or chicken directed against neuron-, astrocyte- and compartment-specific marker proteins and against CCL2, respectively (see Table 1). Brain sections were incubated with cocktails of primary antibodies overnight at 4 °C. On the next day, sections were washed three times with TBS and were then incubated with biotinylated donkey anti-rabbit, 1:400 and Cy3-conjugated donkey anti-mouse, -goat and -chicken, 1:200 (Dianova) secondary antibodies, respectively, followed by Cy2-conjugated streptavidin 1:100 (Dianova) for 60 min at room temperature. After mounting the brain sections on microscope slides, cellular nuclei were counterstained with ToPro3 (1:10,000; Life Technologies).

Confocal laser scanning microscopy

Confocal laser scanning microscopy (LSM 510, Zeiss, Oberkochen, Germany) was performed to reveal co-localization of isoQC and intracellular compartment markers as well as with CCL2. For Cy2-labeled antigens (green fluorescence), an argon laser with 488 nm excitation and 510 nm emission wavelength was used applying a low-range band pass (505–530 nm). For Cy3-labeled antigens, a helium–neon laser with 543 nm excitation and 570 nm emission was used applying high-range band pass (560–615 nm). The nuclear staining compound ToPro3 was visualized by excitation at 642 nm and emission at 661 nm.

Mouse primary neuronal and astrocyte cultures

Primary neuronal cell cultures were derived from fetal mouse brain at gestation day 16 as described by Löffner et al. [27]. After 3 days in vitro, cultures were treated with 10 µM cytosine-1-β-d-arabinofuranoside to suppress the growth of dividing cells, mainly of astroglial origin. Astrocyte-rich primary cell cultures were derived from brains of newborn mice according to Löffner et al. [27] and were maintained in DMEM-based medium. Cells were cultured at 37 °C in a humidified atmosphere with 95 % air/5 % CO2 and the medium was renewed every 1–3 days. After 7 days in culture, astrocytes were incubated in Abeta (5 µM), pGlu-Abeta (5 µM), LPS (1 µg/ml medium; O55:B5, Sigma), IFN-γ (20 ng/ml medium; Sigma) or a combination of LPS/IFN-γ for 12, 24, 48 and 72 h, respectively. Abeta peptides were synthesized in 50 µmol scale on Fmoc-Val/Ala-NovaSyn-TGA resin (0.15 mmol/g) using an automated Symphony Synthesizer (Rainin) as described in detail in [51]. The crude peptides were dissolved in HFIP for preparative HPLC and further purified by RP-HPLC [51]. Peptide purity and identity were confirmed by analytical HPLC (150 × 4.6, 5 µ Source or Gemini) and matrix-assisted laser desorption ionization mass spectroscopy (MALDI-MS). Prior to use, the peptides were dissolved in 1 mM HFIP and incubated at room temperature for 2 h to solubilise peptides and to monomerise β-sheet protein aggregates. Following evaporation of HFIP the peptides were dissolved in Optimem medium and diluted to the final concentration indicated.

Human brain tissue

Case recruitment and characterization of human brain tissue

Case recruitment and autopsy were performed in accordance with guidelines effective at Banner Sun Health Research Institute Brain Donation Program of Sun City, AZ, USA [4]. The required consent was obtained for all cases. The definite diagnosis of AD for all cases used in this study was based on the presence of neurofibrillary tangles and neuritic plaques in the hippocampal formation and neocortical areas and met the criteria of the National Institute on Aging (NIA) and the Consortium to establish a registry for AD (CERAD) [34]. Brain tissue of temporal cortex (Brodmann Area 22) from 6 controls and 6 age-matched AD cases was used for isoQC, CCL2, GFAP and pGlu-Abeta immunohistochemistry. Additionally, for biochemical analyses, temporal cortex (Brodmann Area 22) of 7 control cases and 5 AD cases with a very short postmortem interval of 1.5–5.5 h and a thorough clinical characterization was used (Table 2). Anatomical structures and cortical layers were identified using consecutive Nissl-stained sections and the atlas of the human brain [30].

Tissue preparation

For immunohistochemistry, 15-mm-thick tissue blocks were prepared in the frontal plane according to the atlas of
the human brain [30] and were fixed in 4 % paraformaldehyde in 0.1 M PBS, pH 7.4 for 3–4 days. Areas containing the regions of interest were cryoprotected in 30 % sucrose in 0.1 M PBS, pH 7.4. Series of 30-µm-thick sections were cut on a freezing microtome and collected in PBS containing 0.1 % sodium azide.

For biochemical analyses including Abeta and CCL2 ELISAs, and for quantitative RT-PCR to detect isoQC and CCL2 transcripts, unfixed temporal cortex tissue with a short postmortem interval was stored at −80 °C (see Table 2). Brain tissue (10 % w/v) was homogenized in TBS (20 mM Tris, 137 mM NaCl, pH 7.6) containing protease inhibitor cocktail (Complete Mini, Roche), sonicated and then centrifuged at 75,500×g for 1 h at 4 °C and the supernatant was stored at −80 °C. Abeta peptides were sequentially extracted with TBS/1 % Triton X-100 (TBS/triton fraction), 2 % SDS in distilled water (SDS fraction), and 70 % formic acid (FA fraction). The combined SDS and FA fractions were considered as the insoluble pool of Abeta.

For determination of CCL2, brain tissue was homogenized (Precellys homogenizer, Peqlab) in the threefold volume (w/v) of ice-cold ELISA blocker (Thermo Scientific) containing protease inhibitors. The homogenate was centrifuged (10 min, 15,000×g), the supernatant removed and subjected to another centrifugation step (30 min, 25,000×g). The final supernatant was shock-frozen and stored at −80 °C.

**Immunohistochemistry of human brain tissue**

**Nissl staining**

Coronal sections of the human hippocampus were mounted on gelatin-coated slides and stained in 0.1 % cresyl violet according to standard protocols.

**Single labeling isoQC and CCL2 immunohistochemistry**

All immunohistochemical procedures were performed on free-floating brain sections. Immunohistochemistry to detect isoQC and CCL2 in human brain was performed using the rabbit anti-isoQC antiserum 3285 (1:500) and the mouse monoclonal CCL2 antibody MAB2791 (1:500), respectively. Brain sections were treated with 2 % H2O2 in 60 % methanol for 1 h, to abolish endogenous peroxidase activity. Unspecific staining was blocked in PBS-T containing 2 % BSA, 0.3 % milk powder and 0.5 % normal donkey serum before incubating brain sections with the primary antibodies at 4 °C overnight. The following day, sections were incubated with secondary biotinylated donkey anti-rabbit or donkey anti-mouse antibodies (Dianova; 1:1,000) for 60 min at room temperature followed by the ABC method which comprised incubation with complexed streptavidin-biotinylated horseradish peroxidase. Incubations were separated by washing steps (3 times 5 min in PBS-T). Binding of peroxidase was visualized by incubation with 2 mg DAB, 20 mg nickel ammonium sulfate and 2.5 µl H2O2 per 5 ml Tris buffer (0.05 M; pH 8.0) for 1–2 min, resulting in black labeling.

**Double and triple labeling immunohistochemistry**

Simultaneous immunohistochemical double and triple labeling of isoQC and its putative substrate CCL2 in combination with the astrocyte marker GFAP or with pGlu-Abeta were performed by incubations of brain slices in cocktails of primary antibodies from different species (Table 1) at 4 °C overnight following the procedure for mouse brain described above.

**qRT-PCR for isoQC and CCL2**

Mouse and human brain tissue samples and cultured primary mouse astrocytes were homogenized using a Precellys homogenizer with 1.4-mm ceramic beads (5,000 rpm, 30 s, Peqlab). RNA was isolated using the NucleoSpin RNA II kit (Macherey–Nagel) according to the manufacturer’s instructions. RNA concentration was measured using a NanoDrop 2000 spectrophotometer (Peqlab). RNA (0.1 µg) was reverse transcribed to cDNA using random primers (Roche) and Superscript III (Life Technologies). Quantitative real-time PCR was performed in a Rotorgene3000 (Corbett Research) using the Rotor-Gene SYBR Green PCR kit and the Quantitect primer assay HsQPCTL (Qiagen), or specific primers for HsCCL2, MsCCL2 and MsQPCTL synthesized by Metabion (Martinsried, Germany) [8, 23]. Relative amounts of gene expression were determined with the Rotorgene software version 6.1 in comparative quantitation mode. Normalization was done against the most stably expressed reference gene YWHAZ identified using Normfinder [3]. The PCR was verified by product melting curves and single amplicons were confirmed by agarose gel electrophoresis.

**Abeta and CCL2 ELISAs**

Specific ELISAs to detect Abeta x-42 and pGlu-Abeta3-42 (IBL, Hamburg) in human brain were performed as described by Schilling et al. [53]. CCL2 concentrations in mouse and human brain were quantified by ELISA (Thermo Scientific) as described earlier [8]. All samples were analyzed in triplicate and the concentrations of the respective Abeta peptides present in temporal cortex were calculated from a standard curve.
were compared to the corrected values of the β-actin bands. Ground and then the corrected values of the isoQC bands were evaluated by densitometric image analysis using the luminol detection system as described above. The blots were digitalized by the software GelCapture and the images were analyzed by the software software package TINA 2.0 (RAYTEST, Straubenhardt, Germany). The sum of gray values over each individual band obtained by densitometry was corrected for background and then the corrected values of the isoQC bands were compared to the corrected values of the β-actin bands.

Statistical analyses

Statistical analyses of qRT-PCR, ELISA and Western blot data were done by one-way ANOVA followed by Bonferroni post hoc test. Statistically significant differences are given for p values of <0.05 (*), <0.01 (**) and <0.001 (***). Statistical results were calculated using the unpaired t test with Welch’s correction. Correlation analyses of mRNA, ELISA and MMSE data were performed by calculating Pearson’s correlation coefficient r with GraphPad Prism4 software.

**Results**

**IsoQC expression in mouse brain and co-localization with CCL2**

In sagittal brain sections of 4-month-old mice, widespread isoQC immunoreactivity was observed in numerous brain regions from olfactory bulb to cerebellum and spinal cord (Fig. 1a). To determine the specificity of this unexpectedly abundant isoQC labeling, brain tissue of wild-type, isoQC knock-out and QC knock-out mice was analyzed. The labeling generated by the isoQC antiserum 3285 in wild-type mouse brain was completely absent in isoQC knock-out but not in QC knock-out mouse brain tissue demonstrating the specificity of this antiserum for isoQC (Fig. 1b). In wild-type mouse brain, significant proportions of neurons in neocortical (cingulate, frontal, parietal, piriform, entorhinal cortex), hippocampal (indusium griseum, cornu ammonis 1–4, dentate gyrus) and subcortical (Edinger–Westphal nucleus, habenular and cochlear nucleus, locus coeruleus) brain structures were found to be isoQC-immunoreactive (Fig. 1c, d). The intensity of the isoQC labeling was strongest in hippocampal pyramidal, granular cells and indusium griseum, habenular, Edinger–Westphal nucleus, piriform and entorhinal cortex neurons (Fig. 1c, d).

In the unmanipulated 4-month-old mouse brain, the expression of isoQC was restricted to neurons as shown by co-localization with the neuronal marker HuC/D and by the absence of isoQC labeling in HuC/D-negative cells (Fig. 2a). Intracellularly, isoQC was present in endoplasmic reticulum and Golgi structures as shown by co-localization with calreticulin and with syntaxin-6, respectively (Fig. 2b). Neurons immunoreactive for isoQC frequently co-expressed its putative substrate CCL2 in mouse brain and in mouse primary neurons (Fig. 2c). The conversion of Glu-CCL2 by recombinant isoQC was analyzed applying a kinetic assay that is based on consumption of NADH in a coupled reaction [52] (Fig. 2d). The progress curve was in accordance with a curve modeled according to the integrated form of the Michaelis–Menten equation, enabling the determination of the kinetic parameters $K_M$ and $k_{cat}$.
The kinetic data showed that CCL2 is converted by isoQC, but with lower efficiency compared to smaller peptide substrates. The observed co-localization of isoQC and CCL2 within intracellular compartments, i.e., at higher concentration of substrate and enzyme due to compartmentalization, might thus be important to facilitate the rather slow turnover of CCL2.

Up-regulation of isoQC and CCL2 expression in APP transgenic Tg2576 mice

To reveal a possible effect of transgenic human APP expression and Abeta plaque formation on the expression of isoQC and its putative substrate CCL2, both transcripts were quantified in neocortex of 17-month-old wild-type and APP transgenic Tg2576 mice. The isoQC mRNA levels were increased by a factor of 2.35 in neocortex of Tg2576 mice compared to wild-type littersmates (Fig. 3a). A statistically significant up-regulation by 55% was also observed for CCL2 transcript levels in brains of Tg2576 mice, indicating a pro-inflammatory response (Fig. 3a). The qRT-PCR data were validated by the demonstration of an up-regulation of GFAP mRNA, a well-known astrocytic response to Abeta plaque pathology (Fig. 3a).

The isoQC and pGlu-CCL2 protein levels quantified by Western blot analysis and ELISA, however, were not significantly increased in cortex of Tg2576 mice compared to wild-type littermates (Fig. 3a). This is also illustrated by similar neuronal immunofluorescent labeling intensity for isoQC and for CCL2 in cortex of wild-type compared to Tg2576 mice (Fig. 3b).

However, with regard to the cell type-specific isoQC and CCL2 expression, we observed remarkable differences between aged wild-type and Tg2576 mice. While isoQC and CCL2 were neuron-specifically expressed in wild-type mice, both proteins were additionally induced in neocortical reactive astrocytes in proximity of Abeta plaques of 17-month-old Tg2576 mice (Fig. 3c, d). There was a gradient in the number of isoQC- and CCL2-immunoreactive astrocytes per area from the plaque core towards the plaque periphery ranging from 21 isoQC- and 17 CCL2-immunoreactive astrocytes per 50,000 µm² in the core to 3 isoQC- and 2 CCL2-immunoreactive astrocytes per 50,000 µm² in the periphery (Fig. 3c). This indicates an Abeta-dependent mechanism of the induction of both proteins.

Simultaneous induction of isoQC and CCL2 in mouse primary astrocytes

Next, we were interested in establishing a cellular model that allows investigating the regulation of isoQC and CCL2 in astrocytes. Therefore, mouse primary astrocytes were cultured and the mRNA and protein levels of isoQC and CCL2 were analyzed under control conditions and after stimulation with Abeta peptides, to mimic a pathogenic situation present at the sites of Abeta deposits in brains of Tg2576 mice and AD patients. Additionally, to reveal whether a general, non-AD-related inflammatory stimulation induces astrocytic isoQC and CCL2 expression, astrocytes were also treated with LPS, IFN-γ, as well as a combination of both substances, for different time periods.

While only weak immunocytochemical signals for isoQC and CCL2 protein were detected in untreated astrocytes, both proteins were transiently induced upon Abeta and pGlu-Abeta stimulation (Fig. 4a). CCL2 was maximally increased to 264% (at 24 h of pGlu-Abeta stimulation) and to 240% (at 48 h of Abeta stimulation), respectively, and declined to untreated control levels at 72 h after the onset of (pGlu)-Abeta treatment (Fig. 4b). The statistically significant induction of isoQC immunoreactivity was less pronounced after treatment with both Abeta variants but already present at 24 h and persisted until 72 h of treatment (Fig. 4b). Correlation analyses between expression levels of isoQC and CCL2 in untreated cells (Fig. 4b1), Abeta-stimulated cells (Fig. 4b2) and pGlu-Abeta-stimulated cells (Fig. 4b3) revealed a co-regulation of both proteins under all experimental conditions. In these analyses, data from all time points of one type of treatment were pooled.

The increased isoQC and CCL2 protein levels detected are not based on elevated expression of the respective mRNAs as demonstrated by qRT-PCR (Fig. 4c). There were no correlations between isoQC and CCL2 transcript levels for any of the treatments performed (Fig. 4c1–3).

This is in contrast to findings following a general pro-inflammatory challenge (LPS/IFN-γ stimulation), which revealed co-regulation of both isoQC and CCL2 transcript and protein expression in mouse primary astrocytes (see Supplementary Information 1).
 IsoQC and CCL2 expression in human control and AD cortex

To reveal a possible role of isoQC and CCL2 in AD, immunohistochemical labeling of human cortex from control and AD subjects was performed. In control tissue, a weak to moderate neuronal isoQC labeling across all cortical layers was observed (Fig. 5a). In contrast, a stronger neocortical isoQC labeling with the most robust staining intensity being present in layer III pyramidal neurons was detected in AD brain tissue (Fig. 5a). A similar labeling pattern and a higher staining intensity in layer III pyramidal neurons of AD subjects were also demonstrated for the isoQC substrate CCL2 (Fig. 5b).

In AD brain tissue, both isoQC and CCL2 immunoreactivity were detected in Abeta plaque-associated glial-like cells (insets in Fig. 5a, b). Based on the cellular morphology and on observations made in Tg2576 mouse brain (compare Fig. 3d), we assumed these glial cells to be most likely astrocytes. To validate this presumption, triple immunofluorescent labelings of isoQC, CCL2 and GFAP on well-preserved human brain tissue were performed. The resulting co-localization clearly demonstrated the co-induction of isoQC and CCL2 in Abeta plaque-associated reactive astrocytes (Fig. 5c) and supports the notion of an Abeta-driven inflammatory response involving isoQC-mediated pGlu-CCL2 formation. Quantitative analysis of plaque-related astrocytic isoQC and CCL2 expression revealed a steeply decreasing density of immunoreactive astrocytes (number of astrocytes per 50,000 µm²) from 13 isoQC- and 14 CCL2-expressing astrocytes per area in the plaque core, and 3 isoQC- and 4 CCL2-immunoreactive astrocytes in the adjacent rim around the plaque to 2 isoQC- and 2 CCL2-positive astrocytes in the outer rim most distant to the plaque, respectively (Fig. 5d). The Abeta plaque-associated expression of both proteins by reactive astrocytes was robust in 4 out of 6 and moderate in the remaining 2 AD cases. In controls, only one out of 6 cases displayed isoQC and CCL2 immunoreactivity associated with discrete Abeta deposits.

In the second set of human brain tissue samples, quantitative biochemical and molecular biological analyses were performed with the aim (1) to validate a possible role of isoQC in pGlu-Abeta and pGlu-CCL2 formation in human brain and (2) to analyze biochemical alterations such as expression of isoQC as well as pGlu-Abeta and pGlu-CCL2 formation with regard to a possible association with the clinical severity of AD as assessed by MMSE.

To address this issue, pathologically and clinically well-characterized brain samples with a short postmortem interval were used (Table 2). By using qRT-PCR, an increase of isoQC mRNA levels to 235 ± 38 % and of CCL2 mRNA levels to 572 ± 139 % in AD temporal cortex compared to controls was detected (Fig. 6a; \( p < 0.05 \)). Furthermore, the concentrations of CCL2 and pGlu-CCL2 in temporal cortex of control and AD cases were quantified by ELISA. Interestingly, pGlu-CCL2 accounted for more than 90 % of total CCL2 in both conditions. In controls, 193.6 pg/ml CCL2 and 205.6 pg/ml pGlu-CCL2 were detected, indicating complete conversion of CCL2 into its pGlu-modified variant. In postmortem brains from AD subjects, pGlu-CCL2 levels were significantly higher than in control cases (Fig. 6a; \( p < 0.05 \)) and represented 98.1 % of total CCL2 (451.2 pg/ml CCL2 and 442.7 pg/ml pGlu-CCL2).

Correlation of isoQC and CCL2 with MMSE

To validate a possible role of isoQC in increased pGlu-CCL2 formation in human brain as well as in cognitive decline in AD, a series of correlation analyses plotting biochemical and clinical parameters from individual control and AD cases was performed.

Analyses revealed a strong correlation between increased levels of isoQC mRNA and low MMSE scores \( (r = -0.7220; \ p = 0.0080) \) and, similarly, between increased levels of CCL2 mRNA and low MMSE scores \( (r = -0.6124; \ p = 0.0270) \) (Fig. 6b, c).

However, correlation analysis revealed that there was no co-regulation of isoQC and CCL2 mRNA levels (Fig. 6d). Yet, CCL2 mRNA and protein levels displayed a strong positive correlation, validating the underlying measurements of mRNA and protein concentrations (Fig. 6e). Just as high isoQC mRNA and CCL2 mRNA concentrations, high pGlu-CCL2 protein levels strongly correlated with a decline in MMSE \( (r = -0.6336; \ p = 0.0180) \) (Fig. 6f).

Additionally, we investigated a possible interrelation between the amount of isoQC mRNA and the accumulation of Abeta and of pGlu-Abeta. While there was no correlation between isoQC transcript levels and total Abeta42...
concentrations (Fig. 6g), a strong correlation between elevated isoQC mRNA levels and increased pGlu-Abeta became evident ($r = 0.6663$; $p = 0.0180$) (Fig. 6h). This provides further evidence for a role of isoQC in pGlu-Abeta formation, but not in Abeta generation in general.

Discussion

In the present study, the expression pattern of isoQC in mouse brain is reported for the first time and we provide evidence for an implication of isoQC-driven CCL2 expression and stabilization in chronic inflammation typical for brains of AD patients and APP transgenic mouse models.

Using a highly specific affinity-purified antiserum, a surprisingly wide-spread distribution of isoQC protein expression in mouse brain was demonstrated. In particular, distinct and neuron-specific isoQC immunoreactivity was detected in many neocortical, hippocampal, subcortical and cerebellar structures of normal wild-type mice. Since brain-specific functions and substrates of isoQC are not yet known, this observation was unexpected and calls for an investigation of biological functions of isoQC in brain. The differential substrate specificity of QC and isoQC appears to arise from their distinct subcellular localization and not from enzymatic characteristics. An example is the thyrotropin-releasing hormone (TRH) tripeptide Gln-His-Pro which is generated from its precursor during maturation by prohormone convertases 1 and 3 and carboxypeptidase E/D in secretory granules [7, 14] and, therefore, is purely a substrate of QC, but not of Golgi-resident isoQC. On the other hand, the monocyte chemoattractant protein-1, CCL2, was demonstrated to be pGlu-modified and thus converted into a biologically active state in peripheral organs by isoQC, but not by QC [8].

The kinetic data shown here indicate that CCL2 is converted by isoQC, but with lower efficiency compared to smaller peptide substrates. Based on these experimental observations and on the reported role of CCL2 in AD [58, 60], we here addressed a possible interrelationship of isoQC and CCL2 in brain. Indeed, double immunofluorescent labeling revealed a co-localization of both proteins in mouse brain neurons and in cultured primary neurons. This co-localization of isoQC and CCL2 within intracellular compartments, i.e. at higher concentration of substrate and enzyme due to compartmentalization, might be important to facilitate the rather slow turnover of CCL2.

We also observed an up-regulation of isoQC and CCL2 mRNA levels and the induction of the enzyme isoQC and its putative substrate CCL2 in reactive astrocytes in proximity of Abeta plaques in Tg2576 mice. Interestingly, this astrocytic co-induction of both proteins followed a gradient from the plaque core towards the periphery, which suggests an Abeta-dependent mechanism. This co-induction of both proteins in the same cell type is indicative of a coordinated inflammatory response to recruit peripheral blood monocytes and other immune cells to loci of pathogenic protein aggregation. The resulting chronic gliosis may also contribute to aspects of AD pathology and to a decline in cognitive performance, a notion which is supported by a previous pharmacological treatment study. When young APP transgenic Tg2576 mice were treated with an inhibitor of QC/isoQC, pGlu-Abeta formation, total Abeta load and gliosis were reduced and memory deficits were ameliorated [53]. This is consistent with the view that prevention of pathogenic pGlu-Abeta seed formation has specific anti-inflammatory and mnemonic effects. However, when this pharmacological treatment was initiated in older mice—i.e. after initial pGlu-Abeta seed formation had already taken place—the total Abeta plaque load was not reduced, but accompanying microgliosis was ameliorated and context fear memory was improved in aged Tg2576 mice [53]. We hypothesize that the effects observed in this study can be attributed at least in part to inhibition of isoQC. Reduced enzymatic activity may then result in lowered astrocytic CCL2 pGlu modification, minimized CCL2 biological activity, alleviated microglial recruitment and diminished pro-inflammatory response, which collectively may lead to improved performance in the cognitive tasks tested. This scenario would be in line with recent studies demonstrating that an inhibitor of CCL2 synthesis protects neurons against Abeta toxicity [57] and that inhibition of microglial activation reduces cognitive deficits in a transgenic mouse model for AD [5].

The induction of AD-related proteins in reactive astrocytes following a number of challenges was consistently reported in the past for APP, BACE1 and γ-secretase components [17, 37, 64] and is expanded here to isoQC and its substrate CCL2. To corroborate this finding, we used a primary astrocyte model to study aspects of isoQC/CCL2 regulation under conditions of Abeta pathology. As a stimulation model, Abeta and pGlu-Abeta peptides were applied to astrocytic cultures. We observed a co-induction of both isoQC and CCL2 on the protein but not on the mRNA level. Under these conditions, there was a strong correlation between isoQC and CCL2 protein expression in individual culture wells, which was not observed for the transcript level. Thus, this model appears to be useful to study regulatory mechanisms of isoQC and CCL2 co-induction in astroglial cells. Additionally, astrocytes and microglia—but not neurons—were recently reported to be the source of N-terminally truncated Abeta peptides, another pathogenic QC/isoQC substrate [39].

Some of the observations made in APP transgenic Tg2576 mice were mirrored in brains of AD patients. In immunohistochemically processed sections of the temporal
neocortex, a robust expression of isoQC in pyramidal neurons was conspicuous and much less pronounced in control cases. Additionally, isoQC was expressed by reactive astrocytes which also displayed CCL2 immunoreactivity in proximity to Abeta deposits. This indicates that similar mechanisms of isoQC and CCL2 regulation are active in the diseased human brain and in the transgenic mouse model analyzed. It is important to note that isoQC and CCL2 proteins were not detected in activated microglial cells of APP transgenic Tg2576 mice and AD subjects (data not shown).

Next, we sought to correlate the cognitive status of elderly humans with isoQC expression levels and pGlu-CCL2 protein levels in brain to assess the clinical significance of our findings. To address this issue, isoQC expression was quantified in temporal cortex (Brodmann Area 22), a part of the associative cortex involved in language processing [48]. Brain tissue with a very short postmortem delay and a well-documented clinical status was received from the Banner Health Brain Donation Program. Biochemical and molecular biological analyses included qRT-PCR to detect isoQC and CCL2 mRNAs as well as ELISA to quantify pGlu-Abeta and pGlu-CCL2 protein concentrations. Matching our immunohistochemical data, isoQC transcript levels were shown to be elevated in AD temporal cortex, as were total Abeta42 and pGlu-Abeta peptide concentrations and pGlu-CCL2 levels.

For individual cases, mRNA and protein measurements were correlated with the respective cognitive status as measured by MMSE. Here, a good correlation between isoQC mRNA levels and the concentration of pGlu-CCL2 was detected, supporting the notion of isoQC-catalyzed pGlu-CCL2 formation in human cortex contributing to pathological events. However, since only end-stage AD cases were analyzed in this study, it is not possible to draw conclusions on the sequence of events taking place. There were also strong inverse correlations between CCL2 mRNA and pGlu-CCL2 protein concentrations and MMSE. This is not surprising since neuroinflammatory events are characteristic of AD. On the other hand, CCL2 signaling is known to be enhanced in breast cancer, a condition present in the case AD3 of our cohort, which displays particularly high pGlu-CCL2 levels. Thus, the issue of possible co-morbidities should be addressed in further studies with larger cohorts. Taken together, this study points towards a specific role of isoQC and pGlu-Abeta in further studies with larger cohorts. Taken together, this study points towards a specific role of isoQC and pGlu-Abeta formation and by isoQC-driven CCL2 stabilization maintaining chronic inflammatory events which collectively affect cognition.

Acknowledgments We are grateful to the Banner Sun Health Research Institute Brain Donation Program of Sun City, Arizona for the provision of human brain tissue. The Brain Donation Program is supported by the National Institute on Aging [P30 AG19610 Arizona Alzheimer’s Disease Core Center], the Arizona Department of Health Services [contract 211002, Arizona Alzheimer’s Research Center], the Arizona Biomedical Research Commission [contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson’s Disease Consortium] and the Michael J. Fox Foundation for Parkinson’s Research. We thank Dr. K. Hsiao-Ashe for providing Tg2576 mice. This work was supported by the German Federal Department of Education, Science and Technology, BMBF [Grant #0316033A to HUD, Grant #0316033B to SR and Grant #0316033F to SS]. Further, this work was supported by the German Research Foundation RO 2226/13-1 to SR and the Alzheimer Forschungsinitiative e.V. (AFI #11861) to MM.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Acero G, Manutcharian K, Vasilievko V, Munguia ME, Govezensky T, Coronas G, Luz-Madrigal A, Cribbis DH, Gervokian G (2009) Immunodominant epitope and properties of pyroglutamate-modified Aβ-specific antibodies produced in rabbits. J Neuroimmunol 213:39–46
2. Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Seldmeier R, Raber KA, Cynis H, Röncke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rüssemblies M, Waniek A, Roßner S, Schilling S, Osman AP, Demuth HU, von Hörsten S (2011) Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. J Neurosci 31:12790–12801
3. Andersen CL, Ledet-Jensen J, Ørntoft T (2004) Normalization of real-time quantitative RT-PCR data: a model based variance estimation approach to identify genes suited for normalization—applied to bladder- and colon-cancer data-sets. Cancer Res 64:5245–5250
4. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2008) The Sun Health
Research Institute Brain Donation Program: description and experience, 1987–2007. Cell Tissue Bank 9:229–245

5. Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM (2012) Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer’s disease. Neurodegener Dis 9:187–198

6. Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: a comparative overview. Mol Neurobiol 50:534–544

7. Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS (1987) An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. J Biol Chem 262:8532–8536

8. Cynis H, Hoffmann T, Friedrich D, Kehlen A, Gans K, Klein- schmidt M, Rahfeld JU, Wolf R, Wernmann M, Stephan A, Haegel M, Sedlmeyer R, Graubner S, Jia W, Müller A, Eichentopf R, Heiser U, Seifert F, Quax PH, de Vries MR, Hesse I, Trautwein D, Wollert U, Berg S, Freyse EJ, Schilling S, Demuth HU (2011) The isoenzyme of glutaminyl cyclase is an important regulator of monocytic infiltration under inflammatory conditions. EMBO Mol Med 3:545–558

9. Cynis H, Kehlen A, Haegel M, Hoffmann T, Heiser U, Fujii M, Shibazaki Y, Yoneyama H, Schilling S, Demuth HU (2013) Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol 94:217–225

10. Cynis H, Rahfeld JU, Stephan A, Kehlen A, Koch B, Wernmann M, Demuth HU, Schilling S (2008) Inhibition of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. J Mol Biol 379:966–980

11. Cynis H, Scheel E, Sadowski TC, Schilling S, Demuth HU (2008) Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 47:7405–7413

12. Cynis H, Schilling S, Bodnar M, Hoffmann T, Heiser U, Sadowski TC, Demuth HU (2006) Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochem Biophys Acta 1764:1618–1625

13. D’Arrigo C, Tabaton M, Verco A (2009) N-terminal truncated beta amyloid oligomer formation and progression of neurocognitive dysfunction. PLoS One 4(7):e6197

14. Fischer WH, Spiess J (1987) Identification of a mammalian glutaminyl cyclase as the enzyme responsible for pyroglutamate (pGlu) A beta formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem 286:4454–4460

15. Hellvard A, Maresz K, Schilling S, Graubner S, Heiser U, Johnson R, Cynis H, Demuth HU, Potempa J, Mydel P (2013) Glutaminyl cyclases as novel targets for the treatment of septic arthritis. J Infect Dis 207:768–777

16. Heneka MT, O’Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm 117:919–947

17. Hommet C, Mondon K, Camus V, Ribeiro MJ, Beaufréel M, Arcilet N, Corcia F, Paccalin M, Minier F, Gosselin T, Page G, Guillo- teau D, Chalon S (2013) Neuroinflammation and β amyloid deposition in Alzheimer’s disease: in vivo quantification with molecular imaging. Dement Geriatr Cogn Disord 37:1–18

18. Jawhar S, Wirtsho S, Schilling S, Graubner S, Demuth HU, Bayer TA (2011) Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A beta formation, suggests involvement in the protein maturation machinery. J Mol Biol 379:966–980

19. Kehlen A, Haegel M, Menge K, Gans K, Immel UD, Hoang-Vu C, Klönisch T, Demuth HU (2013) Role of glutaminyl cyclases in thyroid carcinomas. Endocr Relat Cancer 20:79–90

20. Kitoya T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T (2009) AAV12-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses glialis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther 17:803–809

21. Kitoya T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T (2009) CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One 4(7):e6197

22. Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC, Alzheimer’s Disease Neuroimaging Initiative (2013) Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology 80:648–654

23. Löfler F, Lohmann SM, Walkhoff B, Walter U, Hamprecht B (1986) Immunocytochemical characterization of neuron-rich primary cultures of embryonic rat brain cells by established neuronal and glial markers and by monoclonal antibodies against cyclic nucleotide-dependent protein kinases and the synaptic vesicle protein synapsin I. Brain Res 363:205–225

24. Mai JK, Assheuer J, Paxinos G (2004) Atlas of the human brain. Academic Press, San Diego

25. McCall G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherry RA, Bush AI (2009) The Caenorhabditis elegans Aβ1-42 model of Alzheimer’s disease predominantly expresses Aβ1-42. J Biol Chem 284:22697–22702

26. McGeer EG, McGeer PL (2010) Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 19:355–361

27. Miraval M, Calero M, Takao M, Roher AE, Ghetty B, Vidal R (2005) Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry 44:10810–10821
34. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486

35. Morawski M, Hartlage-Rübsamen M, Jäger C, Waniek A, Roßner S (2010) Distinct glutaminyl cyclase expression in Edinger–Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer’s disease. Acta Neuropathol 120:195–207

36. Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, Roßner S (2014) Glutaminyl cyclase in human cortex: correlation with (pGlu)-Abeta load and cognitive decline in Alzheimer’s disease. J Alzheimers Dis 39:385–400

37. Nadler Y, Alexandrovich A, Grigoriadis N, Hartmann T, Rao KS, Shohami E, Stein R (2008) Increased expression of the gammasecretase components presenilin-1 and nicastrin in acrictically affected astrocytes and microglia following traumatic brain injury. Glia 56:552–567

38. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanan T, Taylor K, Wildtgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexendu A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature 485:651–655

39. Oberstein TJ, Spitzer P, Klafki HW, Linning P, Neff F, Knüller HJ, Lewczuk P, Wältfang J, Kornhuber J, Maler JM (2015) Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides. Neurobiol Dis 73:24–35

40. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armiricati A, D’Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saito TC, Markesbery W, Gambetti P, Tabaton M (2005) Beta-amyloid is different in normal aging and in Alzheimer’s disease. J Biol Chem 280:34186–34192

41. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K (2010) Distinct glutaminyl cyclase expression in Edinger–Westphal nucleus, locus coeruleus and nucleus basalis Meynert in Alzheimer’s disease pathogenesis. J Neuroinflamm 8:150

42. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235–246

43. Russo C, Schettini G, Saio TC, Hulette C, Lippa C, Markesbery W, Cattaneo A, Cenni A, Cavallero F, Zona G, Afonso A, Schilling S, Demuth HU (2015) Neuroprotective effects of the glutaminyl cyclase inhibitor Bindarit in familial and sporadic Alzheimer’s disease. J Alzheimers Dis 57:1357–1368

44. Russo C, Violani E, Salis S, Venezia D, Dolcini V, Damonte G, Benatti U, D’Arrigo C, Patrone E, Carlo P, Schettini G (2002) Amyloid-beta precursor protein (AβPP) and carboxyl-terminal heterogeneity of β-amyloid peptides. Neurobiol Aging 23:105–113

45. Saido TC, Iwatsubo T, Mannhart S, Hoffmann M, Demuth HU (2008) Generation of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. J Neurochem 106:1225–1236

46. Saido TC, Yamao H, Iwatsubo T, Kawashima S (1995) Dominant and differential deposition of β-amyloid peptides and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neurosci Lett 215:173–176

47. Saido TC, Yamato H, Iwatsubo T, Kawashima S (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 215:173–176

48. Saygin AP, Dick F, Wilson SM, Drongen NF, Bates E (2003) Neural resources for processing language and environmental sounds: evidence from aphasia. Brain 126:928–945

49. Schilling S, Appel T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, von Hörsten S, Demuth HU (2008) Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. J Neurochem 106:1225–1236

50. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU (2004) Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 563:191–196

51. Schilling S, Baumer T, Schoppa M, Manhart S, Scheel E, Böhm G, Demuth HU (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45:12393–12399

52. Schilling S, Manhart S, Hoffmann T, Ludwig HH, Wasternack C, Demuth HU (2003) Substrate specificity of glutaminyl cyclases from plants and animals. Biol Chem 384:1583–1592

53. Schilling S, Zeitischel U, Hoffmann T, Heiser U, Francke M, Kahlen A, Holzer M, Hutter-Paier B, Prokesh M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Roßner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology. Nat Med 14:1106–1111

54. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU (2009) Pyroglutamate formation influences solubility and amyloidogenicity of amyloid-β peptides. Biochemistry 48:7072–7078

55. Schiuttemaker A, Krogholfer MA, Boellaard R, van der Flier WM, Kriet RW, van der Doef TF, Knol DL, Windhorst AD, Luurtsema G, Barkhof F, Jonker K, Lammersma AA, Scheltens P, van Berckel BN (2013) Microglial activation in Alzheimer’s disease: an (R)-[11C]P1PK11195 positron emission tomography study. Neurobiol Aging 34:128–136

56. Sevalle J, Amoyel A, Robert P, Fournié-Zaluski MC, Roques B, Checler F (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid-β-peptide. J Neurochem 109:248–256

57. Severini C, Passeri PP, Ciotti M, Florenzano F, Possenti R, Zona C, Di Matteo A, Guglielmotti A, Calissano P, Pachter J, Mercanti D (2014) Bindarit, inhibitor of CCL2 synthesis, protects neurons against amyloid-β-induced toxicity. J Alzheimers Dis 38:281–293

58. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol 19:392–398

59. Stephan A, Wermann M, von Bohlen A, Koch B, Cynis H, Demuth HU, Schilling S (2009) Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics. FEBS J 276:6522–6536

60. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 7:e30525

61. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118:487–496

62. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease—a double-edged sword. Neuro 35:419–432

63. Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikizu T (2005) Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol 166:1475–1485

64. Zhao J, O’Connor T, Vassar R (2011) The contribution of activated astrocytes to Abeta production: implications for Alzheimer’s disease pathogenesis. J Neuroinflamm 8:150